HMGB1 and infectious otitis media: To examine whether HMGB1 could restore CXCL2 expression and CRC tumorigenesis in Gsdmc2–4 deficient mice, we intraperitoneally injected vehicle or 2 μg per mouse recombinant HMGB1 every other day for 30 days in the AOM‐DSS model.